FR900359

News alerts, weekly reports and conference planners

Company:

Astellas, Icahn School of Medicine at Mount Sinai, Sidney Kimmel Cancer Center, Thomas Jefferson University

Drug class:

Gαq-11 protein inhibitor

Related drugs:

‹

›

GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D

Associations
(3)